8 Gene Panel for Barretts Esophagus

This biomarker is also known as:
  • 8 Gene Panel for Barretts Esophagus
  • 8-gene Panel for Barrett's Esophagus
  • Meltzer 8-marker panel for Esophageal Adenocarcinoma


Eight methylation biomarkers - p16, RUNX3, HPP1 (HGNC name TMEFF2), NELL1, TAC1, SST, AKAP12 and CDH13 - were tested in a restrospective multicenter double-blinded validation study for their accuracy in predicting neoplastic progression in Barretts Esophagus. Hypermethylation of p16, RUNX3 and HPP1 has been show to occur in early Barretts Esophagus-related neoplastic progression and predicts progression risk. Several of the panel (NELL1, TAC1, SST, AKAP12 and CDH13) were also shown to be methylated early and often in Barretts Esophagus-related neoplastic progression.


There are no datasets associated with this biomarker.

QA State: Accepted
HGNC Name:

Panel Details

The following organs have data associated with this biomarker…


Phase: 3
QA State: Under Review
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access to this biomarker.

No other associated resources found.

Version 5.1.0